A recent study published in the New England Journal of Medicine has revealed promising results for patients with congenital adrenal hyperplasia (CAH) who were treated with crinecerfont. The research, conducted by Richard J. Auchus, M.D., Ph.D., and colleagues from the University of Michigan Medical School, showed that crinecerfont led to a significant decrease in the daily glucocorticoid dose compared to a placebo.
The study, presented at the annual meeting of the Endocrine Society in Boston, involved 182 adults with CAH who were randomly assigned to receive either crinecerfont or a placebo for 24 weeks. The results showed that patients in the crinecerfont group experienced a greater reduction in glucocorticoid dose compared to those in the placebo group.
Over the course of the 24-week trial, the researchers observed a decrease in glucocorticoid dose by 27.3% in the crinecerfont group, while the placebo group only saw a 10.3% decrease. Additionally, a higher percentage of patients in the crinecerfont group were able to achieve a physiologic glucocorticoid dose compared to the placebo group.
Notably, at week 4, patients in the crinecerfont group exhibited a decrease in androstenedione levels, while those in the placebo group showed an increase. The most common adverse events reported in both groups were fatigue and headache.
The authors of the study concluded that crinecerfont therapy could lead to a significant reduction in glucocorticoid administration for adults with classic CAH, allowing for a transition to more physiologic doses.
It is important to note that several authors involved in the study disclosed ties to biopharmaceutical companies, including Neurocrine Biosciences, the manufacturer of crinecerfont, which also funded the research.
